Network Pharmacology Approach for Predicting Targets of Zishen Yutai Pills on Premature Ovarian Insufficiency
article
OA: hybrid
CC0
⤵ 2 in-corpus citations
AI-generated summary
This network pharmacology study identified 476 target genes for Zishen Yutai Pills in treating premature ovarian insufficiency, implicating inflamm-aging and glucose metabolism, potentially via the HIF-1 signaling pathway.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
METHODS: A comprehensive strategy based on several Chinese herb databases and chemical compound databases was established to screen active compounds of ZSYTP and predict target genes. For network pharmacological analysis, network construction and gene enrichment analysis were conducted and further verified by molecular docking. RESULTS: A total of 476 target genes of ZSYTP were obtained from 205 active compounds. 13 herbs of ZSYTP overlapped on 8 active compounds based on the compound-target-disease network (C-T network). 20 biological processes and 9 pathways were strongly connected to the targets of ZSYTP in treating POI, including negative regulation of gene expression, mRNA metabolic process, hypoxia-inducible factor 1 (HIF-1) signaling pathway, and gluconeogenesis. Finally, molecular docking was visualized. CONCLUSION: Intriguingly, the signal pathways and biological processes uncovered in this study implicate inflamm-aging and glucose metabolism as potential pathological mechanisms of POI. The therapeutic effect of ZSYTP could be mediated by regulating glucose metabolism and HIF-1 signal pathway. Collectively, this study sheds light on the therapeutic potential of ZSYTP on POI.
My notes (saved in your browser only)
Citation neighborhood (sparse)
Too few in-corpus citations on either side for a chart; here are the lists.
Cites (2)
- ESHRE Guideline: management of women with premature ovarian insufficiency 2016
- The Treatment of Complementary and Alternative Medicine on Premature Ovarian Failure 2021
Cited by (2)
References (68)
- ESHRE Guideline: management of women with premature ovarian insufficiency via openalex
- The Treatment of Complementary and Alternative Medicine on Premature Ovarian Failure via openalex
- doi:10.4274/tjod.00334 via openalex
- doi:10.1056/nejmcp0808697 via openalex
- doi:10.1080/13697130601135672 via openalex
- doi:10.1093/nar/gkm795 via openalex
- W255996521 via openalex
- doi:10.7150/ijms.5630 via openalex
- doi:10.1038/s41419-018-1196-3 via openalex
- doi:10.1093/nar/28.1.235 via openalex
- doi:10.1080/13697130601114891 via openalex
- doi:10.1016/j.arr.2007.09.002 via openalex
- doi:10.1186/1758-2946-6-13 via openalex
- doi:10.1093/nar/gkz382 via openalex
- doi:10.4103/0976-7800.104467 via openalex
- doi:10.1111/j.1365-2265.2007.03073.x via openalex
- doi:10.1038/77498 via openalex
- W2352520505 via openalex
- doi:10.1016/j.fertnstert.2014.12.106 via openalex
- doi:10.1093/nar/gkj067 via openalex
- doi:10.1038/srep21146 via openalex
- doi:10.1016/j.redox.2017.03.005 via openalex
- doi:10.1002/jcc.21256 via openalex
- doi:10.3402/jev.v4.27066 via openalex
- doi:10.1016/j.yrtph.2016.07.015 via openalex
- doi:10.1111/1753-0407.12190 via openalex
- doi:10.1038/ncb1596 via openalex
- doi:10.1016/j.yrtph.2016.12.001 via openalex
- doi:10.1097/00002030-200301030-00006 via openalex
- doi:10.1038/nchembio.118 via openalex
- doi:10.1093/bioinformatics/btp101 via openalex
- doi:10.1016/j.jep.2012.09.051 via openalex
- doi:10.1530/eje-18-0602 via openalex
- doi:10.1111/j.1749-6632.2000.tb06651.x via openalex
- doi:10.1371/journal.pone.0015939 via openalex
- doi:10.1016/j.mad.2017.02.008 via openalex
- doi:10.1210/jc.2016-1141 via openalex
- doi:10.1093/nar/30.1.412 via openalex
- doi:10.2337/diab.40.4.405 via openalex
- doi:10.2337/dc12-1020 via openalex
- doi:10.1177/0960327119865588 via openalex
- W3004408948 via openalex
- doi:10.19540/j.cnki.cjcmm.20180419.005 via openalex
- doi:10.1155/2020/3582648 via openalex
- W6609701964 via openalex
- doi:10.1016/j.jep.2020.113045 via openalex
- doi:10.1210/endocr/bqaa038 via openalex
- doi:10.1177/0963689720923575 via openalex
- doi:10.1016/j.jpba.2020.113570 via openalex
- doi:10.1093/nar/gkaa971 via openalex
- doi:10.1016/j.cmet.2020.07.007 via openalex
- doi:10.1002/jcp.29725 via openalex
- doi:10.5603/ep.a2020.0002 via openalex
- doi:10.1186/s13048-018-0400-5 via openalex
- doi:10.1007/s42000-019-00134-4 via openalex
- doi:10.1177/1933719116667218 via openalex
- doi:10.4314/ijmu.v2i2.39851 via openalex
- doi:10.1001/jamacardio.2016.2415 via openalex
- doi:10.1016/s0169-409x(00)00129-0 via openalex
- doi:10.1002/jcp.26507 via openalex
- doi:10.1093/database/bat018 via openalex
- doi:10.3390/ijms13066964 via openalex
- doi:10.1016/j.jep.2021.114109 via openalex
- doi:10.1016/j.chom.2017.03.002 via openalex
- doi:10.1007/s10735-015-9609-4 via openalex
- doi:10.5603/gp.a2018.0062 via openalex
- doi:10.1071/rd18222 via openalex
- doi:10.1101/gr.1239303 via openalex
Cited by (2)
Source provenance
- openalex
- last seen: 2026-05-10T11:54:40.589718+00:00
License: CC0
· commercial use OK